ORO. O. Rummo

O. O. Rummo

*This is an algorithmically generated author record based on publicly available information.

O. O. Rummo has a total of 183 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Results of epidemiological surveillance in a surgical intensive care unit: a prospective single-center study

    by L. Kuzmenkova, P. Prilutsky, A. Dzyadzko, A. Shcherba, O. Rummo, Л. Л. Кузьменкова, П. С. Прилуцкий, А. М. Дзядзько, А. Е. Щерба, О. О. Руммо

    Objective. To evaluate the trends in healthcare-associated infection (HAI) rates and analyze the effectiveness of the infection control system in a surgical anesthesiology and intensive care unit (ICU) among patients undergoing abdominal surgeries and liver or kidney transplantation. Materials and methods. A single-center prospective study was conducted at the ICU of the Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology. Over the period from 2019 to 2025, a total of 10,567 patients were treated (82.2 % – surgical profile, 30.6 % – post-transplant recipients). Epidemiological surveillance included registration of HAIs using standard case definitions, microbiological monitoring, and assessment of antimicrobial resistance. Data processing was performed using WHONET 5.6 and IBM SPSS Statistics 26.0 software. Results. The overall incidence of healthcare-associated infections (HAIs) peaked in 2021 at 12.5 (95 % CI (9.7–15.5)) per 100 patients, then decreased to 5.6 in 2022 and stabilized in 2023–2025 at 4.6–5.9 per 100 treated patients. The rate of ventilatorassociated pneumonia decreased from 27.3 (2021) to 12.8 (2025) per 1000 ventilator-days (p = 0.04). The rate of surgical site infections decreased from 1.0 (2019) to 0.5 (2025) per 100 operations (p = 0.03). A shift in the timing of late-onset infections was noted (VAP – on day 10 of mechanical ventilation, CAUTI – on day 13 of catheterization). An increase in the proportion of Gram-positive flora (from 25 to 33 %, p = 0.06) and Candida fungi ( Candida non-albicans – 58%, including C. auris – 31 %) was revealed. The proportion of imported cases was 21% (95 % CI (16.7–25.9)). An increase in the susceptibility of major Gram-negative pathogens to carbapenems and polymyxins was observed (p < 0.05 for most comparisons). Conclusion. The implementation of epidemiological surveillance, adherence to infection control measures, and optimization of antimicrobial therapy are associated with a reduction in HAI incidence and the prevalence of carbapenem-resistant microorganisms, as well as with a mitigation of the consequences of imported epidemiologically significant pathogens.

  • Еvaluation of the effectiveness of systemic application of mesenchymal stem cells for induction of immunosuppression in liver transplantation

    by S. Korotkov, V. Shamruk, N. Dedyulya, I. Romanova, S. Krivenko, O. Rummo

    Objective. To evaluate the efficacy of systemic application of mesenchymal stem cells (MSCs) for induction of immunosuppression in liver transplantation. Materials and methods. A prospective randomized study was conducted to evaluate the effectiveness of systemic administration of mesenchymal stem cells (MSCs) for immunosuppression induction in liver transplantation. The study included 30 patients: 15 received MSC therapy, 15 received standard immunosuppressive therapy. Systemic administration of MSCs was performed twice: intraoperatively and on the 4th day after transplantation at a dose of 2×10 6 cells/kg. Results. MSCs application contributed to faster normalization of biochemical parameters (AST, ALT, bilirubin), reduced incidence of acute rejection (20 % vs 33.3 %), decreased expression of matrix metalloproteinase-10 in the graft, and maintained effective immunosuppression at lower tacrolimus concentrations (3.1 ng/ml vs 4.7 ng/ml). Immunophenotyping confirmed the immunomodulatory effect of MSCs through stimulation of regulatory lymphocyte populations and suppression of effector components of the immune response. Clinically, this resulted in reduced length of stay in the intensive care unit and overall hospitalization duration. Conclusion. The results demonstrate the safety and efficacy of MSCs as a component of induction immunosuppressive therapy in liver transplantation.

  • Minimization of immunosuppressive therapy using mesenchymal stem cells in liver transplantation in patients with renal injury

    by S. V. Korotkov, E. G. Yurkina, A. A. Symanovich, E. A. Nazarova, I. P. Shturich, А. M. Dzyadz’kO, S. I. Krivenko, O. O. Rummo

    The aim of the study was to evaluate the possibility of using mesenchymal stem cells (MSCs) to minimize the nephrotoxic effects of tacrolimus in liver transplant recipients with high risk of developing of acute kidney injury. In a randomized prospective study, 60 patients who had undergone liver transplantation participated: 30 patients received combined MSC therapy (local intraportal and systemic intravenous administration), 30 patients received standard immunosuppressive therapy. In the MSC group, a faster recovery of graft function with an accelerated decrease in ALT on days 7 and 10 ( p < 0.05) was established with a significantly lower tacrolimus concentration at all follow-up periods (on day 14: 4.8 (2.4; 5.7) ng/ml compared to 6.3 (4.2; 8.8) ng/ml in the control group, p = 0.005). The frequency of immuno- logical graft dysfunction was 20% in both groups. However, in the MSC group exhibited a lower rejection activity index (RAI 6 (4; 7) versus 7 (4; 8) points) and no cases of humoral rejection. Analysis of the immunophenotype revealed the formation of an “immunosuppressive window” by the 4th day of the postoperative period in the MSC group, characterized by a decrease in the absolute number of CD16+56+ natural killer cells and CD3+CD4+ effector memory T-cells with an increase in the level of dendritic cells and immunosuppressive B1a-lymphocytes. The minimization of tacrolimus contributed to faster recovery of renal function with lower creatinine levels ( p < 0.05) and higher GFR values ( p < 0.05). The duration of stay in the intensive care unit and the total duration of hospitalization in the MSC group were shorter.

  • RENAL INJURY CONTINUUM IN LIVER TRANSPLANTATION: THE ROLE OF MESENCHYMAL STEM CELLS IN MINIMIZING TACROLIMUS NEPHROTOXICITY

    by Transplantology And Hematology Minsk Scientific And Practical Center For Surgery, S. V. Korotkov, D. A. Fedoruk, A. M. Fedoruk, S. I. Krivenko, O. O. Rummo

    Background. Acute kidney injury (AKI) is a common complication occurring in up to 95% of liver transplantations and carrying a 2.96-fold increased risk of mortality and a 3.76-fold higher risk of liver graft failure. Objective. To present the concept of renal injury continuum in liver transplantation and evaluate the effectiveness of mesenchymal stem cells (MSCs) in minimizing tacrolimus nephrotoxicity. Materials and methods. Liver transplant patients were studied using KDIGO criteria for diagnosing acute kidney injury (AKI) and chronic kidney disease (CKD). Results. AKI developed in 39-58% of liver recipients. The main risk factors included initial condition severity (Child-Pugh ≥10 points), intraoperative blood loss (≥1200 ml) and tacrolimus nephrotoxicity (58% of cases). In the long term, 68.2% of patients developed stage 3 CKD, which correlated with high tacrolimus concentrations. There has been detected an association between the degree of renal dysfunction and the risk of immunological complications (up to 40% in CKD stage 3C). The use of MSCs allowed for the reduction of tacrolimus concentration without rejection rate increase, it accelerated renal function recovery, and reduced the incidence of CKD in the long term. The immunomodulatory effect of MSCs was confirmed by a decreased number of effector cells (CD16+56+ NK cells, CD3+CD4+ TEM, CD3+CD8+TEMRA) as well as by reduced anti-HLA antibody levels. Conclusions. Renal injury in liver transplantation represents a continuum of interrelated processes covering all stages of transplantation. The use of MSCs promotes immunological tolerance formation, allowing for safe tacrolimus dosage tapering and nephrotoxicity reduction, thus improving both renal and overall clinical outcomes in liver transplant recipients.

  • Open Access

    Pancreatic cystic tumors: literature review and early surgical outcomes at a certain center

    by O. O. Rummo, T. M. Chernyshov, A. E. Shcherba, S. V. Korotkov, Л. В. Кирковский

    Aim. To analyze the outcomes of patients with pancreatic cystic tumors managed at a high-volume hepato-pancreatobiliary (HPB) surgery center.Materials and Methods. Between 2014 and 2025, a total of 386 pancreatic resections were performed, with 82 (21.24%) for pancreatic cystic tumors. The mean patient age was 51 ± 10.7 years, and 63.4% of the patients were female.Results. Of the patients who underwent surgical operations, 10 (12.1%) had branch-duct intraductal papillary mucinous neoplasms (IPMNs), and 13 (15.88%) had main-duct IPMNs. Additionally, 25 patients (30.53%) were treated for mucinous cystic neoplasms, 1 (1.21%) for a cystic neuroendocrine tumor, 21 (25.63%) for solid pseudopapillary neoplasms, and 12 (14.63%) for serous cystadenomas. A retrospective pathohistological analysis of 121 cases of pancreatic head cancer following pancreatoduodenectomy revealed that 31 patients (25.61%) had developed adenocarcinoma associated with mucinous ductal neoplasms of various types.Conclusion. Pancreatic cystic tumors exhibit variable biological behaviors, necessitating differential diagnosis and management.


  • Open Access

    International consensus on diagnosing and managing pancreatic serous and mucinous cystic neoplasms

    by I. E. Khatkov, V. V. Tsvirkun, P. S. Tyutyunnik, A. R.O. Aliev, S. M. Akhmadzoda, I. G. Bakulin, B. B. Baimakhanov, B. Kh. Bebezov, N. A. Bodunova, D. S. Bordin, et al.

    In 2023, with the approval of the leadership of the Hepato-Pancreato-Biliary Association of Commonwealth of Independent States, a consensus study was initiated and conducted on the diagnosis, management, and follow-up of patients with serous and mucinous neoplasms of the pancreas. Based on an extensive literature review, responses to each of the 22 questions posed were formulated and compiled into a Consensus Document. A total of 44 experts representing 27 institutions across 9 countries participated in the preparation of the Consensus. The Delphi method was employed for voting, and ultimately, including the results of votes on selected statements during the final conference, consensus was achieved on all questions.


  • Open Access

    Mesenchymal stem cells in liver transplantation: аssessment of long-term results

    by S. V. Korotkov, E. A. Nazarova, E. G. Yurkina, В. В. Смольникова, V. Yu. Grinevich, E. A. Yanushevskaya, A. Yu. Startseva, A. E. Shcherba, S. I. Krivenko, O. O. Rummo, et al.

    Introduction. Transplantation is an effective method of treating patients with end stage liver diseases. Long-term results are determined by two main factors: the development of immunological complications and calcineurin inhibitor nephrotoxity. Application of mesenchymal stem cells (MSCs), which modulate the immune response, is a promising effective method to optimize the treatment results in patients after liver transplantation.The objective of the study was to evaluate the long-term results of mesenchymal stem cells application in liver transplantation.Material and methods. A retrospective study was performed, which included 186 patients after liver transplantation (2015–2023). The MSC group (n=93) received MSCs according to four protocols: local, systemic, combined administration, therapy for acute kidney injury; the control group (n=93) received the standard treatment. The median follow-up was 3 (2;5) years, the follow-up period being from 1-8 years. The patient survival, graft and renal function, depth of immunosuppressive therapy, anti-HLA antibody levels, and lymphocyte immunophenotype were assessed.Results. In the MSC group the incidence of immunological dysfunction of the liver allograft was decreased (22% versus 40%, pConclusion. Using MSCs in liver transplantation improves long-term outcomes by reducing the incidence of immunological complications, preserves the renal function, and reduces the need for high-dose immunosuppression.

  • Open Access

    Intraportal induction of mesenchymal stem cells for immunosuppression induction in liver transplantation

    by S. V. Korotkov, E. A. Primakova, A. A. Symanovich, О. А. Лебедь, T. V. Lebedeva, A. E. Shcherba, S. I. Krivenko, O. O. Rummo

    Background. Despite the effectiveness of modern immunosuppressive therapy protocols, acute rejection remains a significant challenge in liver transplantation (LT), occurring in up to 40% of cases. One promising strategy to improve graft tolerance and reduce rejection rates is the use of mesenchymal stem cells (MSCs). Administering MSCs directly into the regional circulation of the transplanted liver offers the potential to enhance the effects of standard immunosuppressive therapy by exerting a localized immunosuppressive effect at the graft site. Objective: to evaluate the clinical efficacy of intraportal administration of MSCs during the induction phase of immunosuppressive therapy in patients undergoing LT. Materials and methods. A randomized prospective study was conducted involving two groups of LT recipients. In the experimental group (n = 14), patients received an intraportal infusion of MSCs during transplantation at a dose of 20 × 106 cells. The control group (n = 14) underwent standard transplant reperfusion without MSC administration. The study assessed the safety of the MSC infusion procedure, graft function, incidence and severity of acute rejection, renal function, and tacrolimus levels. Additional assessments included histological and immunohistochemical analyses, as well as fluorescence in situ hybridization (FISH). Results. No complications associated with MSC administration were observed. The MSC group demonstrated faster restoration of graft function, with significantly lower levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) by postoperative day 4 (p < 0.05), and normalization of AST achieved by day 10. The incidence of acute rejection was lower in the MSC group (21%) compared to the control group (28%), with only mild to moderate rejection observed in the MSC group. Additionally, expression of matrix metalloproteinase-10 (MMP10) was significantly reduced in the MSC group (p = 0.01). Tacrolimus levels were lower in the MSC group, yet adequate immunosuppression was maintained. This correlated with faster renal function recovery, with serum creatinine levels on day 4 significantly lower in the MSC group compared to controls (80 vs 101 μmol/L, p < 0.05). FISH analysis confirmed the presence of MSCs within the liver graft tissue on postoperative day 7. Conclusion. Intraportal administration of MSCs during LT is a safe approach that enhances faster graft function recovery, reduces the severity of acute rejection, and mitigates tacrolimus-associated nephrotoxicity. These findings support the potential of MSC therapy as a valuable adjunct to standard immunosuppressive regimens in LT.

  • Open Access

    Characteristics of immune status in patients after liver transplantation with mesenchymal stem cell therapy

    by S. V. Korotkov, В. В. Смольникова, V. Yu. Grinevich, A. E. Shcherba, S. I. Krivenko, O. O. Rummo

    The aim of the study was evaluation of the characteristics of the immunophenotype of peripheral blood mononuclear cells in patients after liver transplantation with systemic mesenchymal stem cells (MSCs) therapy. A randomized prospective study was conducted involving 30 recipients. Patients in the MSC group (n = 15) received standard immunosuppressive therapy in combination with systemic application of MSCs, and patients in the control group (n = 15) received only standard immunosuppression. The analysis of the immunophenotype of peripheral blood mononuclear cells was performed by flow cytometry with assessment of the main populations and subpopulations of lymphocytes and dendritic cells. The application of MSCs resulted in an immunotolerant phenotype, characterized by an increase in the level of regulatory T cells and B1a lymphocytes, a decrease in the number of effector CD4+ memory T cells and B lymphocytes, as well as a modulation of dendritic cells activity. The MSC group demonstrated a lower incidence of acute rejection (20 % compared to 33 %), lower expression of MMP10 in the graft, accelerated recovery of liver function, and the ability to reduce the dose of Tacrolimus without the risk of rejection. These results indicate the potential of MSCs to serve as an additional method of immunosuppression in liver transplantation

  • Open Access

    Comparative analysis of the profile of expression of molecular markers of mesenchymal stem cells obtained from placental-umbilical cord complex tissues, adipose tissue and bone marrow

    by E. G. Yurkina, S. I. Krivenko, В. В. Смольникова, E. A. Primakova, E. A. Nazarova, A. A. Symanovich, N. I. Dedyulya, I. A. Romanova, D. Yu. Efimov, A. E. Shcherba, et al.

    Mesenchymal stem cells (MSCs) are multifunctional adult stem cells that can be derived from various tissues, such as adult adipose tissue, peripheral blood, bone marrow, neonatal placenta, and umbilical cord tissue. MSCs have the capacity for self-renewal and multidirectional differentiation. Despite the absence of differences in the expression of the main surface markers, MSCs obtained from tissues of the placenta-umbilical cord complex, adipose tissue and bone marrow differ significantly in their molecular profile. Cellular heterogeneity is ubiquitous across MSC cultures from different species and tissues. During the course of the study, the expression level of cell surface markers that characterize the heterogeneity of MSCs obtained from various sources was assessed. MSCs from all tissues express typical MSC markers on their surface, including CD13, CD73, CD105 and CD90, in the absence of expression of hematopoietic markers (CD14, CD34 and CD45), costimulatory molecules CD86, membrane protein CD154, adhesion molecules CD15, and markers of embryonic stem cells (TRA-1-81 and TRA-1-60R). However, they differed in the expression of stemness markers (October 4, Nanog), coinhibitory molecules (CD273, CD274, and CD200), cell adhesion molecules CD146, surface antigen SSEA-4, and transcription factor GATA4. The results on the molecular profile of MSCs as a heterogeneous cell population allow for the scientific substantiation of the choice of tissue source for the creation of biomedical cell products with specified therapeutic properties.